NEW YORK (GenomeWeb) – Q2 Solutions, a clinical trials laboratory services organization, said today that it has established a collaboration framework with Illumina for companion diagnostics development.

Under the terms of the agreement, Q2 Solutions will use Illumina's MiSeqDx instrument, which has US Food and Drug Administration 510(k) clearance, to develop next-generation sequencing-based companion diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.